BIO-RAD LABORATORIES ($BIO) posted quarterly earnings results on Wednesday, October 29th. The company reported earnings of $2.26 per share, beating estimates of $1.95 by $0.31. The company also reported revenue of $653,000,000, missing estimates of $657,813,505 by $-4,813,505.
You can see Quiver Quantitative's $BIO stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BIO-RAD LABORATORIES Hedge Fund Activity
We have seen 168 institutional investors add shares of BIO-RAD LABORATORIES stock to their portfolio, and 265 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FIRST EAGLE INVESTMENT MANAGEMENT, LLC added 951,123 shares (+60.7%) to their portfolio in Q2 2025, for an estimated $229,525,002
- VAN ECK ASSOCIATES CORP removed 556,476 shares (-93.3%) from their portfolio in Q2 2025, for an estimated $134,288,788
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 366,058 shares (-95.6%) from their portfolio in Q2 2025, for an estimated $88,337,116
- BLACKROCK, INC. removed 259,061 shares (-12.8%) from their portfolio in Q2 2025, for an estimated $62,516,600
- DEERFIELD MANAGEMENT COMPANY, L.P. added 226,070 shares (+inf%) to their portfolio in Q2 2025, for an estimated $54,555,212
- DIMENSIONAL FUND ADVISORS LP added 122,528 shares (+14.0%) to their portfolio in Q2 2025, for an estimated $29,568,456
- NUVEEN, LLC removed 121,467 shares (-80.3%) from their portfolio in Q2 2025, for an estimated $29,312,416
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BIO-RAD LABORATORIES Government Contracts
We have seen $3,729,321 of award payments to $BIO over the last year.
Here are some of the awards which we have have seen pay out the most over the last year:
- LYPHOCHEK WHOLE BLOOD METALS CONTROL - QUALITY CONTROL REAGENTS: $279,038
- IMMUNOLOGY: $261,724
- CONSUMABLES AND REAGENT PRODUCTS FOR SEROLOGICAL AUTOMATED ANALYZER SYSTEMS.: $244,260
- HIV DIAGNOSTICS LABORATORY CONSUMABLES AND REAGENTS FOR BIO-RAD EQUIPMENT: $211,619
- BIOPLEX REAGENTS AND CONSUMABLES: $200,000
To track government contracts to publicy traded companies, check out Quiver Quantitative's government contracts dashboard.
BIO-RAD LABORATORIES Analyst Ratings
Wall Street analysts have issued reports on $BIO in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- RBC Capital issued a "Outperform" rating on 08/01/2025
To track analyst ratings and price targets for BIO-RAD LABORATORIES, check out Quiver Quantitative's $BIO forecast page.
BIO-RAD LABORATORIES Price Targets
Multiple analysts have issued price targets for $BIO recently. We have seen 2 analysts offer price targets for $BIO in the last 6 months, with a median target of $337.0.
Here are some recent targets:
- Conor McNamara from RBC Capital set a target price of $409.0 on 08/01/2025
- Brandon Couillard from Wells Fargo set a target price of $265.0 on 08/01/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
